Please Wait.....
Report
Uterine Fibroid Treatment Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others), By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids), By End User (Hospital Pharmacies, Retail Pharmacies, Others), By Region & Competition, 2020-2030F
Market Report I 2025-04-11 I 180 Pages I TechSci Research
Global Uterine Fibroid Treatment Drugs Market was valued at USD 4.85 billion in 2024 and is projected to register steady growth at a compound annual growth rate (CAGR) of 4.40% through 2030.
Market expansion is being driven by several key factors, including the rising global prevalence of uterine fibroids, increasing preference for non-surgical treatment options, advancements in pharmaceutical research, and greater accessibility to healthcare services. Uterine fibroids, also referred to as leiomyomas, are among the most common benign tumors affecting women of reproductive age and are often associated with heavy menstrual bleeding, pelvic pain, and fertility complications.
Growing awareness, improved diagnostic practices, and expanded access to treatment have accelerated the adoption of pharmacological therapies. This is particularly evident in the increasing use of gonadotropin-releasing hormone (GnRH) antagonists, progestin-based regimens, and non-hormonal alternatives, reflecting a broader shift in patient preference toward non-invasive therapies over surgical procedures. Ongoing drug innovations, higher regulatory approval rates, and expanding insurance coverage continue to support the market's positive outlook, especially in regions witnessing a surge in fibroid incidence and improved access to care.
Key Market Drivers
Rising Prevalence of Uterine Fibroids
The increasing global prevalence of uterine fibroids is a primary growth driver for the market. These benign pelvic tumors, although non-cancerous, are widespread among women of reproductive age. Due to their frequently asymptomatic nature, actual prevalence is likely underreported. Studies indicate a wide prevalence range from 4.5% to 68.6%, influenced by variables such as diagnostic methods, population demographics, and healthcare availability.
As the number of diagnosed cases continues to rise, so does the demand for effective pharmacological treatment. Factors such as late pregnancies, hormonal imbalances, and a global increase in obesity contribute significantly to the growing incidence of uterine fibroids. For instance, in 2022, one in every eight individuals globally was affected by obesity. Since 1990, obesity rates have more than doubled in adults and quadrupled in adolescents, with 2.5 billion adults classified as overweight, including 890 million with obesity. These health trends further amplify the burden of uterine fibroids and underscore the demand for scalable, non-invasive treatment solutions.
Key Market Challenges
Limited Long-Term Efficacy and Safety Data
While pharmaceutical treatments for uterine fibroids have demonstrated notable effectiveness in managing symptoms, concerns remain regarding their long-term safety and efficacy. Many clinical studies feature relatively short follow-up periods, limiting insights into extended use and sustained outcomes. To ensure continued patient trust and optimize treatment strategies, robust long-term clinical data is essential. Such data will help address safety concerns, inform regulatory decisions, and guide healthcare providers in making evidence-based therapeutic choices.
Key Market Trends
Emergence of Combination Therapies
The market is witnessing a growing interest in combination therapy approaches, integrating uterine fibroid drugs with minimally invasive procedures or complementary hormonal treatments. These integrated solutions offer the potential for enhanced symptom relief, improved patient outcomes, and a more personalized treatment experience.
Combination therapies are especially promising for patients with varying fibroid types, sizes, or symptoms, allowing for tailored care strategies that target fibroids through multiple mechanisms. This approach not only improves therapeutic efficacy but also reduces the likelihood of recurrence, positioning combination treatment as a compelling solution in the evolving landscape of uterine fibroid care.
Key Market Players
- Myovant Sciences Ltd
- Pfizer Inc
- Abbvie Inc
- Ferring BV
- AstraZeneca
- Bayer AG
- Amring Pharmaceuticals Inc
- Watson Pharma Pvt Ltd
Report Scope:
In this report, the Global Uterine Fibroid Treatment Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Uterine Fibroid Treatment Drugs Market, By Drug Class:
o Gonadotropin-Releasing Hormone (Gnrh) Agonists
o Gonadotropin-Releasing Hormone (Gnrh) Antagonists
o Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
o Non-Hormonal Medications
o Others
- Uterine Fibroid Treatment Drugs Market, By Type:
o Subserosal Fibroids
o Intramural Fibroids
o Submucosal Fibroids
o Pedunculated Fibroids
- Uterine Fibroid Treatment Drugs Market, By End User:
o Hospital Pharmacies
o Retail Pharmacies
o Others
- Uterine Fibroid Treatment Drugs Market, By region:
o North America
United States
Mexico
Canada
o Europe
France
Germany
United Kingdom
Italy
Spain
o Asia-Pacific
China
India
South Korea
Japan
Australia
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Competitive Landscape
Uterine Fibroid Treatment Drugs Market.
Available Customizations:
Global Uterine Fibroid Treatment Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Uterine Fibroid Treatment Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
6.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
6.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
6.2.4. By Region
6.2.5. By Company (2024)
6.3. Product Market Map
7. North America Uterine Fibroid Treatment Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Type
7.2.3. By End User
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Uterine Fibroid Treatment Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Type
7.3.1.2.3. By End User
7.3.2. Mexico Uterine Fibroid Treatment Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Type
7.3.2.2.3. By End User
7.3.3. Canada Uterine Fibroid Treatment Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Type
7.3.3.2.3. By End User
8. Europe Uterine Fibroid Treatment Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Type
8.2.3. By End User
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Uterine Fibroid Treatment Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Type
8.3.1.2.3. By End User
8.3.2. Germany Uterine Fibroid Treatment Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Type
8.3.2.2.3. By End User
8.3.3. United Kingdom Uterine Fibroid Treatment Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Type
8.3.3.2.3. By End User
8.3.4. Italy Uterine Fibroid Treatment Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Type
8.3.4.2.3. By End User
8.3.5. Spain Uterine Fibroid Treatment Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Type
8.3.5.2.3. By End User
9. Asia-Pacific Uterine Fibroid Treatment Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Type
9.2.3. By End User
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Uterine Fibroid Treatment Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Type
9.3.1.2.3. By End User
9.3.2. India Uterine Fibroid Treatment Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Type
9.3.2.2.3. By End User
9.3.3. South Korea Uterine Fibroid Treatment Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Type
9.3.3.2.3. By End User
9.3.4. Japan Uterine Fibroid Treatment Drugs Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Class
9.3.4.2.2. By Type
9.3.4.2.3. By End User
9.3.5. Australia Uterine Fibroid Treatment Drugs Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Drug Class
9.3.5.2.2. By Type
9.3.5.2.3. By End User
10. South America Uterine Fibroid Treatment Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Type
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Uterine Fibroid Treatment Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Type
10.3.1.2.3. By End User
10.3.2. Argentina Uterine Fibroid Treatment Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Type
10.3.2.2.3. By End User
10.3.3. Colombia Uterine Fibroid Treatment Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Type
10.3.3.2.3. By End User
11. Middle East and Africa Uterine Fibroid Treatment Drugs Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Class
11.2.2. By Type
11.2.3. By End User
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Uterine Fibroid Treatment Drugs Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Type
11.3.1.2.3. By End User
11.3.2. Saudi Arabia Uterine Fibroid Treatment Drugs Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Type
11.3.2.2.3. By End User
11.3.3. UAE Uterine Fibroid Treatment Drugs Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Class
11.3.3.2.2. By Type
11.3.3.2.3. By End User
11.3.4. Kuwait Uterine Fibroid Treatment Drugs Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Drug Class
11.3.4.2.2. By Type
11.3.4.2.3. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions
14. Policy & Regulatory Landscape
15. Porters Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product
16. Competitive Landscape
16.1. Myovant Sciences Ltd
16.1.1. Business Overview
16.1.2. Product & Service Offerings
16.1.3. Recent Developments
16.1.4. Financials (If Listed)
16.1.5. Key Personnel
16.1.6. SWOT Analysis
16.2. Pfizer Inc
16.3. Abbvie Inc
16.4. Ferring BV
16.5. AstraZeneca
16.6. Bayer AG
16.7. Amring Pharmaceuticals Inc
16.8. Watson Pharma Pvt Ltd
17. Strategic Recommendations
18. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security